November 27, 2017
Patients from the city of Chicago plan a press conference at the doors of the ACGME, Accreditation Council for Graduate Medical Education, regarding procedure requirements as of July 2017, which emphasize patient safety. Moreover, the ACGME require that all complaints undergo submission, only after all available reporting agencies, local and national, have evaluated the complaint.
One patient, Mrs. Maureen Obermeier, filed a lawsuit in the Circuit Court of Cook County L-012426 in 2008, for the failure to produce medical records related to the case, failure to inform the patient of her heart attack, and failure to treat the heart attack sustained during the experimental surgery as part of the motions submitted in this case. Dr. Rajamannan, who is an unpaid expert in this case and author of the Myxo Files, has testified in support of her patient and the events which transpired during the surgery. The case will be part of the complaint filed today at the ACGME and will be discussed during the news conference at noon. A Copy of the complaint will be available to any members of the press who attend the press conference at noon.
In 2017, the most recent investigations began in the State of WI, after the FDA wrote letters to Dr. Rajamannan. As an eye witness, Dr. Nalini Rajamannan, currently a Cardiologist at Most Sacred Heart of Jesus Cardiology, Sheboygan WI, CorVita, Chicago IL, Global Heart Valves, and Visiting Scientist at the Mayo Clinic, Rochester MN, contacted Sheboygan’s Congressman Glenn Grothman, who immediately sent letters to the FDA, followed by questions from Senator Ron Johnson of WI, Chairman of the Homeland Security Committee to the Office of the Inspector General, for delays in reviewing allegations submitted since 2014, as reported by WHBL Radio Sheboygan, WI.
According to the NBC investigation in September 2017, the FDA confirmed the status of the heart devices.
Since 2008, the Senate Finance and Judiciary Committees under Senator Grassley, investigated the testing of the heart valves in patients during open heart surgery.
Today, as of November 27, 2017, after the FDA confirmation of the experimental testing Dr. Rajamannan and three patients who learned of their experimental heart surgeries after the fact, are filing a report with the ACGME, and will appear at noon for a press conference at 401 N Michigan Ave, Chicago IL 60611.
If interested in a copy of the ACGME report please attend the conference tomorrow at noon.
Share article on social media or email: